GSK saw its pharmaceutical business decline by 10% in the US due to high competition in the respiratory drugs market. The company's 5-year average 4.90% dividend yield to counter low capital gains.

GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.

The latest trading session saw GSK (GSK) ending at $41.19, denoting a +0.81% adjustment from its last day's close. The stock lagged the S&P 500's daily gain of 1.11%. Meanwhile, the Dow gained 0.8 ...

GSK's native reporting currency is UK pounds, and shares are traded on the London Stock Exchange. GSK ADS, equivalent to 2 GSK shares, are traded on the NYSE in US$. The underlying performance of ...

In the latest trading session, GSK (GSK) closed at $40.80, marking a +0.27% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow ...

GSK shares dropped by the most in nearly two years after a ruling by the Delaware State Court that ... GSK GSK fell by 9.5%, its worst single-day performance since the 10.1% decline on Aug. 11 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common ... which is more than double the S&P 500's performance over the same time frame. However, ...

GSK plc (NYSE:GSK) is a British multinational pharmaceutical and biotechnology company, that is credited for the development of the first malaria vaccine in 2014, and later for its role alongside ...

In the latest market close, GSK (GSK) reached $39.88, with a -0.55% movement compared to the previous day. This move lagged the S&P 500's daily loss of 0.37%.

GSK (GSK) ended the recent trading session at $39.64, demonstrating a +1.1% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.41%. At the ...